New ways of looking at tumor genetics and dynamics have been developed: the Liquid Biopsy (LB), which has been incorporated into clinical practice as a non-invasive analysis of circulating material derived from tumors, which represents an innovative tool in precision oncology and overcomes the current limitations associated with tissue biopsies. An LB is a new tool of great value, constituting a diagnostic, prognostic, and predictive marker. The elements that make up LB are circulating tumor cells (CTCs) and circulating tumor nucleic acids (ctNA: DNA or RNA) in free cells or contained in exosomes, microvesicles, and platelets. The ctDNA and CTCs are the only one's components with a clinical application approved by the US Food and Drug Administration (FDA).

New ways of looking at tumor genetics and dynamics have been developed: the Liquid Biopsy (LB), which has been incorporated into clinical practice as a noninvasive analysis of circulating material derived from tumors, which represents an innovative tool in precision oncology and overcomes the current limitations associated with tissue biopsies. An LB is a new tool of great value, constituting a diagnostic, prognostic, and predictive marker. The elements that makeup LB are circulating tumor cells (CTCs) and circulating tumor nucleic acids (ctNA: DNA or RNA) in free cells or contained in exosomes, microvesicles, and platelets. The ctDNA and CTCs are the only one's components with a clinical application approved by the US Food and Drug Administration (FDA).

New ways of looking at tumor genetics and dynamics have been developed: the Liquid Biopsy (LB), which has been incorporated into clinical practice as a noninvasive analysis of circulating material derived from tumors, which represents an innovative tool in precision oncology and overcomes the current limitations associated with tissue biopsies. An LB is a new tool of great value, constituting a diagnosis, prognostic, and predictive marker. The elements that makeup LB are circulating tumor cells (CTCs) and circulating tumor nucleic acids (ctNA: DNA or RNA) in free cells or contained in exosomes, microvesicles, and platelets. The ctDNA and CTCs are the only one's components with a clinical application approved by the US Food and Drug Administration (FDA).

تم تطوير طرق جديدة للنظر في جينات الورم وديناميكياته: الخزعة السائلة (LB)، والتي تم دمجها في الممارسة السريرية كتحليل غير جراحي للمواد المتداولة المستمدة من الأورام، والتي تمثل أداة مبتكرة في علم الأورام الدقيق وتتغلب على القيود الحالية المرتبطة بخزعات الأنسجة. LB هي أداة جديدة ذات قيمة كبيرة، وتشكل علامة تشخيصية وتنبؤية وتنبؤية. العناصر التي تشكل LB هي الخلايا السرطانية المنتشرة (CTCs) والأحماض النووية الورمية المنتشرة (ctNA: DNA أو RNA) في الخلايا الحرة أو الموجودة في الجسيمات الخارجية والحويصلات الدقيقة والصفائح الدموية. إن ctDNA و CTCs هما المكونان الوحيدان اللذان لهما تطبيق سريري معتمد من قبل إدارة الغذاء والدواء الأمريكية (FDA).